The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Machine-learning to predict hydroxyurea failure & thromboembolic events in polycythemia vera
Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of machine-learning to predict hydroxyurea failure and incidence of thromboembolic events with hydroxyurea and ruxolitinib switch therapy in polycythemia vera patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
